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ABSTRACT
In 2002, 119 isolates of the Enterobacter cloacae complex were collected randomly from 11 German
laboratories nationwide. Antibiotic susceptibilities were tested by disk-diffusion tests according to CLSI
guidelines, and MICs were determined using Etests. PCRs were performed to amplify all TEM and SHV,
and most CTX-M and OXA b-lactamase genes. PCR products were sequenced to identify the precise
extended spectrum b-lactamase (ESBL) types. Isoelectric focusing (IEF) and PM ⁄PML Etests were used
to conﬁrm production of the respective ESBLs. According to susceptibility tests and CLSI criteria, 49
(40%) isolates were resistant to extended-spectrum cephalosporins. Seven (5.8%) isolates were positive
in at least one of the PCR assays. Sequencing identiﬁed production of TEM-1 b-lactamase genes by three
(2.9%) isolates, and ESBL genes of the CTX-M and SHV b-lactamase families by ﬁve (4.2%) isolates. IEF
conﬁrmed the production of b-lactamases in the expected pI ranges of the respective ESBLs, and four of
the ﬁve ESBL-producers were detected using the PM ⁄PML Etest. All ESBL-producing isolates showed
co-resistance to sulphonamides.
Keywords CTX-M, Enterobacter cloacae complex, epidemiology, extended-spectrum b-lactamases, SHV, TEM
Original submission: 19 September 2004; Revised Submission: 5 September 2005; Accepted: 5 September 2005
Clin Microbiol Infect 2006; 12: 322–330
INTRODUCTION
Members of the Enterobacter cloacae complex have
emerged as increasingly important nosocomial
pathogens, especially in intensive care units
(ICUs) [1]. Preceding therapy with extended-
spectrum cephalosporins (ESCs) is considered to
be a major risk-factor for infections with the E.
cloacae complex, which results mainly from the
intrinsic resistance of these bacteria to most ESCs.
This resistance is associated with production of an
inducible chromosomal Bush group 1 AmpC
b-lactamase. AmpC is produced universally by
Enterobacter spp., and contributes to the selective
advantage of the E. cloacae complex in the pres-
ence of antibiotic pressure [2]. If hyper-produced,
AmpC hydrolyses all penicillins and cephalospo-
rins without being inhibited by clavulanic acid
(CA), tazobactam or sulbactam. Cefepime is an
ESC that is hydrolysed only marginally by AmpC,
but treatment failure with cefepime for Enterob-
acter infection has been reported [3,4], and this has
been explained by reduced production of RomA-
controlled porins in the bacterial cell wall. How-
ever, clinically and epidemiologically, a more
important mode of resistance to ESCs, including
cefepime, is the production of extended-spectrum
b-lactamases (ESBLs).
Production of ESBLs has been observed in
virtually all Enterobacteriaceae of clinical import-
ance, where they may mediate in-vivo resistance
to all cephalosporins [5]. The CLSI (formerly
NCCLS) has proposed methods for the detection
of ESBLs in Escherichia coli and Klebsiella spp.,
based on screening tests with disks containing
cefpodoxime, ceftazidime or cefotaxime, and con-
ﬁrmatory tests exploiting the inhibitory effect of
CA on the hydrolysing action of ESBLs [6]. These
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methods are of limited value with organisms
of the E. cloacae complex that produce an AmpC
b-lactamase that is not inhibited by CA [7].
Because of this diagnostic dilemma, precise data
concerning the prevalence of ESBLs in the E.
cloacae complex are scarce, although reports have
occurred worldwide [8–11]. Reports of local out-
breaks with ESBL-producing Enterobacter spp. are
increasing, but regional epidemiological studies
of ESBL prevalence in the E. cloacae complex are
few in number [12–14]. Therefore, the present
study used a combination of molecular and
phenotypic tests to assess the frequency of ESBL
genes among a collection of E. cloacae complex
isolates recovered from 11 geographically separ-
ated centres in Germany. This is the ﬁrst multi-
centre epidemiological study in Germany of
ESBLs produced by members of the E. cloacae
complex.
MATERIALS AND METHODS
Bacteria
Each isolate was recovered from a different hospitalised
patient between January and June 2002, and was identiﬁed
biochemically using the API 20E kit (bioMe´rieux, Marcy
l’E´toile, France). Isolates were collected in a random manner,
i.e., colleagues in the different centres were asked to collect up
to 15 consecutive isolates from various clinical samples, from
different patients and different wards. A speciﬁc request was
made that isolates should be collected randomly and that no
selection criteria should be used (e.g., phenotypic or resistance
characteristics; criteria such as ‘infection or colonisation’, or
‘hospital- or community-acquired’). Ten strains known to
produce different CTX-M ESBLs were used for validation of
the CTX-M PCR: Enterobacter aerogenes CTX-M1; Esch. coli CTX-
M1; Esch. coli CTX-M23; Esch. coli CTX-M33; Klebsiella pneu-
moniae CTX-M1; K. pneumoniae CTX-M3; K. pneumoniae CTX-M
(V77A, D114N, S140A); Klebsiella oxytoca CTX-M1; Proteus
mirabilis CTX-M1; and P. mirabilis CTX-M22.
Antibiotic susceptibility testing
Antibiotic susceptibilities were tested by disk-diffusion tests
(Oxoid, Wesel, Germany) on Mueller-Hinton Agar (Oxoid) at
36C aerobically, following CLSI guidelines [6]. Antibiotics
tested were: ampicillin (AMP), amoxycillin + clavulanic acid
(AMC), piperacillin (PIP), piperacillin + tazobactam (TZP),
piperacillin + sulbactam (SPI), cefoxitin (FOX), ceftazidime
(CAZ), cefotaxime (CTX), cefepime (FEP), ertapenem (ETP),
meropenem (MEM), gentamicin (GEN), tobramycin (TOB) and
trimethoprim + sulphamethoxazole (SXT).
Production of chromosomal AmpC cephalosporinase was
interpreted as follows: no production if isolates were
susceptible to all b-lactam antibiotics tested; basal produc-
tion if isolates were resistant to AMP, AMC and ⁄or FOX;
and hyper-production if isolates were resistant to AMP,
AMC, SPI, FOX and an ESC (i.e., CAZ or CTX). All isolates
with resistance patterns not consistent with basal AmpC
production were analysed further for ESBLs. MICs of several
antibiotics were determined by the Etest method, according
to the manufacturer’s instructions (VIVA-diagnostika,
Cologne, Germany), for all isolates producing ESBLs, an
isolate with basal AmpC-production, and an isolate with
AmpC hyper-production.
Two different phenotypic tests for the production of ESBLs
were performed. First, PM ⁄PML-Etests (VIVA-diagnostika),
which are recommended particularly for the detection of
ESBLs in AmpC-producing bacteria and are based on the
division of the MIC of FEP by the MIC of FEP + CA. If the
resulting quotient is >8, the test is considered positive for ESBL
production. FEP is used because it is the only ESC that is not
hydrolysed signiﬁcantly by AmpC. Second, a modiﬁcation of
the double disk-diffusion test recommended by Bradford [5]
was used, in which FEP (30-lg) disks were placed at a distance
of 15 mm (edge to edge) from a disk containing AMC (20 lg
amoxycillin and 10 lg CA).
Type strains Esch. coli DSM 30083T and E. cloacae ATCC
13047 T were used as negative controls, as they are known not
to harbour ESBL genes. K. pneumoniae strain ATCC 700603,
which produces SHV-18, was used as a positive control [15].
DNA preparation and PCR assays
Bacteria were grown in Luria Bertani broth to an OD600 of 1.0.
An aliquot (100 lL) of the culture was centrifuged for 2 min at
8000 g. The pellet was diluted in 1 mL of distilled water and
boiled for 10 min to release DNA.
TEM, SHV and OXA genes were detected using pairs of
primers modiﬁed from previous studies [16–18] (Table 1).
CTX-M primers were designed according to conserved
regions of gene homologues (Table 1). The gene encoding
the 60-kDa heat shock protein (hsp60) was ampliﬁed [19] as
a control in parallel with each ESBL PCR. Partial sequencing
of the hsp60 genes allowed classiﬁcation of the study isolates
to speciﬁc genotypes of the E. cloacae complex [19]. PCRs
were performed using a Gene Amp 2400 (Perkin-Elmer,
Branchburg, NJ, USA) or an Applied BioSystems GeneAmp
2700 PCR system (Applied Biosystems, Foster City, CA,
USA) with 50 pmol of each primer, 200 lM nucleotide mix,
10 mM Tris-HCl (pH 8.3), 5 mM KCl, 1.5 mM MgCl2 and 2.5
U of standard TaqGold polymerase (Perkin-Elmer) in a total
volume of 50 lL. PCRs comprised 10 min at 95C, followed
by 30 cycles of 30 s at 95C, 30 s at annealing temperature
(see below) and 90 s at 72C, with a ﬁnal elongation step of
15 min at 72C. Annealing temperatures were optimised by
2C increments, starting at 6C below the lowest Tm of the
primer sets used, until speciﬁc, single-band PCR products
were obtained. The eventual annealing temperatures chosen
were 57C for SHV and TEM genes, and 55C for CTX and
OXA genes. PCR products were visualised in agarose 2.0%
w ⁄v gels following electrophoresis and ethidium bromide
staining.
Validation of the CTX-M PCR assay was performed with
the ten control strains listed above. Esch. coli strain DSM 30083T
and E. cloacae strain ATCC 13047T were used as negative
controls for all ESBL PCR assays. K. pneumoniae strain ATCC
700603 was used as positive control for the SHV PCR. Other
control organisms included clinical isolates of Esch. coli and
Pseudomonas aeruginosa that were known to possess either
TEM-1, CTX-M-9 or OXA-10 genes.
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DNA sequencing
Amplicons were sequenced in both directions using the dye
terminator method. Cycle-sequencing reactions were prepared
by adding 0.2 lg of puriﬁed DNA to a 20-lL reaction
containing 4 lL of BigDye dye terminator sequencing mix
(Applied Biosystems) and 0.7 lL of a 5-pM primer solution.
Cycle-sequencing was performed in the GeneAmp PCR
System 2700 with 25 cycles of 96C for 10 s, 55C for 10 s
and 4 min at 60C. Sequences were determined with an ABI
PRISM 377 DNA sequencer (Applied Biosystems). About 1%
of the bases sequenced yielded an ‘N’. These were corrected,
based on the respective reverse sequences, using SeqMan
software (DNAStar, Madison, WI, USA). Sequence data were
analysed using MegAlign (DNAStar) and PAUP v.4.0b10 [20].
Multiple alignment was performed using Clustal V, included
in the MegAlign program. Using PAUP 4.0b10, neighbour-
joining trees [21] were estimated, based on pairwise genetic
distances, on the basis of all substitutions using the Jukes-
Cantor distance parameter.
Isoelectric focusing (IEF) of b-lactamases
IEF was performed by electrophoresis of ultrasonic extracts on
polyacrylamide gels (Servalyt Precast; Serva Electrophoresis,
Heidelberg, Germany) containing ampholytes with a pH range
of 3.5–9.5. b-Lactamases were visualised by staining with
nitrocephin 0.2 mg ⁄mL (Oxoid). This was applied on one of
two focused gels immediately following electrophoresis, and
on the other after it was ﬂooded with 1 mM potassium
clavulanate (CA). This allowed an in-situ distinction between
Bush class 1 b-lactamases (e.g., AmpC) that were insensitive to
CA and Bush class 2 b-lactamases (e.g., TEM- or SHV-like) that
were inhibited by CA. IEF Marker 3–10 (Serva Electrophoresis)
was used as a pI standard and was stained with Coumassie
blue according to the manufacturer’s instructions. K. pneu-
moniae strain ATCC 700603 producing SHV-12, and a clinical
Esch. coli isolate producing TEM-1, were used as controls.
RESULTS
Study isolates
In total, 119 isolates were collected from 11
laboratories (Aachen, ten isolates; Berlin, 12 iso-
lates; Frankfurt, 15 isolates; Freiburg, nine iso-
lates; Gelsenkirchen, ten isolates; Hannover, ten
isolates; Heidelberg, ten isolates; Jena, 11 isolates;
Kiel, 11 isolates; Regensburg, nine isolates; Tueb-
ingen, 12 isolates). The isolates originated from 15
medical centres. The clinical sources of the isolates
were blood cultures (six isolates), respiratory tract
samples (45 isolates), urine (17 isolates), perito-
neum, gall bladder or abdominal ﬁstula samples
(six isolates), medical devices (four isolates), anal
swab (one isolate), skin and wound swabs (24
isolates), vaginal swab (one isolate), eye swabs
(two isolates), and 13 isolates of unspeciﬁed origin.
Twenty (17%) specimens were collected from
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ICUs, nine (8%) from departments of general
medicine, 24 (20%) from surgical departments, 20
(17%) from paediatric departments, three (3%)
from dermatology departments, and one (1%)
from a pathology department; the department
was unspeciﬁed for 42 (35%) specimens.
Susceptibility testing
Results of susceptibility testing are summarised in
Table 2. Most (n = 71; 60%) isolates showed basal
AmpC production, i.e., resistance to AMP, AMC
and ⁄ or FOX. In the disk-diffusion tests, 46 (38%)
isolates were resistant and one (1%) showed
intermediate resistance to CAZ, and 46 (38%)
isolates were resistant and two (2%) showed
intermediate resistance to CTX. Tzelepi et al. [22]
have reported a strong correlation between ESBL
production and resistance to SXT or aminoglyco-
sides. Four (8%) of the 48 isolates that were
resistant or showed intermediate resistance to
CTX and ⁄ or CAZ were also resistant to SXT, one
(2%) was resistant to SXT plus GEN, and one (2%)
was resistant to SXT plusGENplus TOB. One (2%)
isolate was resistant to SXT and showed interme-
diate resistance to GEN and TOB (Table 2).
PCR assays and sequencing
The newly designed CTX-M PCR assay was
validated using ten strains of ﬁve different species
possessing different CTX-M-ESBL genes (Fig. 1A).
All PCR results were positive and a repeat run
yielded identical results. The HSP60 PCR was also
positive for all study isolates.
All 49 isolates with antibiograms not consistent
with basal AmpC production, and 20 isolates with
basal AmpC production, were tested with the
PCRs for TEM, SHV, CTX and OXA genes. All 20
isolates with basal AmpC production were neg-
ative by all four PCRs. Seven ESC-resistant
isolates (5.8% of all isolates; 14.2% of the inter-
mediately-resistant or resistant isolates) were
positive in at least one PCR assay (Fig. 1B). All
PCR-positive isolates were from different centres
and corresponded to the seven SXT-resistant
isolates. Sequencing yielded four identical DNA
sequences (460–470 bp) from the CTX PCR, three
identical sequences (830 bp) from the TEM PCR,
and three identical sequences (867–963 bp) from
the SHV PCR. GenBank searches showed best
similarities of the partial CTX-M sequences to the T
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blaCTX-M-9 or blaCTX-M-16 genes (99% genetic iden-
tity; 100% amino-acid identity with blaCTX-M-9 of
Esch. coli, accession number AF252621 [23] and
blaCTX-M-16, accession number AY033516). The
nucleotide sequence of blaCTX-M-16 differs from
blaCTX-M-9 by the substitution A725G. This region
was not ampliﬁed by this PCR. Other ESBL genes
of the CTX-M family might have been missed,
since it is difﬁcult to design a CTX-M PCR that
detects all genes of the CTX-M family [7]. The
SHV sequences showed best similarity with
blaSHV-12 (100% identity with blaSHV-12 of K.
pneumoniae, accession number X98105 [24]), while
the partial TEM sequences showed best similarity
with blaTEM-1 (100% identity with blaTEM-1 of
K. pneumoniae, accession number AY293072),
which is not an ESBL.
Genotypes of the E. cloacae complex
A recent population study identiﬁed 12 genotypes
within the E. cloacae complex [19]. Following
partial sequencing of the hsp60 gene [19], one
isolate in the present study belonged to genetic
cluster I, four to cluster II, 41 to cluster III, ﬁve to
cluster IV, eight to cluster V, 12 to cluster VI, one
to cluster VII, 40 to cluster VIII, two to cluster IX,
three to cluster XI, one to cluster XII, and one to
pseudo-cluster xiii. The ﬁve isolates producing
ESBLs (Table 2) all belonged to genetic cluster
VIII, which has recently been named subspecies
Enterobacter hormaechei steigerwaltii [25].
IEF
For the ﬁve isolates harbouring ESBL genes,
distinct b-lactamases that were not inhibited by
CA were visualised at pI 7.9. Hence, these
enzymes were assigned to Bush class 1 and
identiﬁed as chromosomally-encoded AmpC
b-lactamases, which are ubiquitous within the
E. cloacae complex. Additional b-lactamase bands
were also observed that were CA-sensitive and
focused at pIs of 8.0, 8.2 and 5.4, corresponding to
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(e.g.) CTX-M-9, SHV-12 and TEM-1 b-lactamases
(Table 2).
MICs
MICs of various antimicrobial agents were deter-
mined for the group of ESBL-producing isolates
(Table 2). For comparison, MICs were also deter-
mined for two random isolates from the group of
71 isolates with basal AmpC production and two
from the group of 43 isolates with AmpC hyper-
production. The MICs of TZP and SPI were
signiﬁcantly lower for the ESBL group than for
the other groups, while those of GEN and SXT
were signiﬁcantly higher (Wilcoxon test; p < 0.01).
Phenotypic ESBL tests
Four of the ﬁve ESBL-producing isolates were
detected with the PM ⁄PML-Etests (Fig. 2), i.e.,
strains EN-293 and EN-331 producing ESBLs of
the CTX-M family, strain EN-335 producing CTX-
M and SHV-12, and strain EN-339 producing
SHV-12 and TEM-1. Numerous microcolonies
were observed in the PM and PML inhibition
zones for isolates EN-293, EN-312, EN-335 and
EN-339, hampering the reading of results. The
disk-diffusion tests detected all ﬁve ESBL-
producers.
DISCUSSION
Nosocomial infections with ESBL-producing En-
terobacteriaceae cause problems in hospitalised
patients worldwide [26,27]. Missed identiﬁcation
of ESBL production by organisms causing infec-
tions has been associated with a signiﬁcant
increase in mortality [28]. It has been recommend-
ed that patients colonised or infected with ESBL-
producing Enterobacteriaceae should be isolated
in private rooms with contact precautions [29,30].
However, little is known about the impact of
ESBLs in organisms belonging to the E. cloacae
complex. One reason for this might be the lack of
practical diagnostic tests for ESBLs in non-Escheri-
chia and non-Klebsiella spp. in diagnostic laborat-
ories [7]. Multicentre surveillance programmes,
such as SENTRY, have provided some regional
prevalence rates (4–44%) for ESBLs in the E.
cloacae complex [10]. Similarly, Crowley and
Ratcliffe [9] reported a high prevalence (33%) of
ESBLs in isolates of Enterobacter spp. from blood
cultures, and described a case of CTX treatment
failure associated with ESBL production.
All of the above studies were based on
isolates pre-selected on the basis of positive
phenotypic tests, and the prevalence rates
reported might have been biased by the fact
that phenotypic tests may not be applicable to
AmpC-producing species. The true prevalence
rates of ESBL genes in populations of isolates
producing Bush class 1 b-lactamases might vary.
In the present study, all isolates with resistance
patterns different from those expected as a
result of basal AmpC production were analysed
genetically for the presence of ESBL genes. This
approach probably provided a more accurate
picture of ESBL rates, although some potential
sources of error must be taken into account.
First, rare isolates that harbour an ESBL gene,
but produce the ESBL at a low level, might
retain the resistance pattern of basal AmpC-
producers. Second, some ESBL genes may not
be detected by the CTX-M and OXA PCRs used
in the study. Nevertheless, the ESBL prevalence
rate of 4.2% observed in the present study was
high compared to that for Esch. coli and K. pneu-
moniae, which were expected to be the species
producing ESBLs most frequently, as ESBL
prevalences of 0.8% and 8.2%, respectively,
were reported for Germany in 2001 [31].
b-Lactamases belonging to the CTX-M family
were the ESBLs encountered most frequently in
the present set of isolates. In a phylogenetic
study, the CTX-M family contained ﬁve major
groups of blaCTX-M-like b-lactamases which were
relatively distinct on both the genetic and the
amino-acid levels, with the groups consisting of
CTX-M-1-like, CTX-M-9-like, CTX-M-8-like, CTX-
M-25-like and CTX-M-2-like enzymes, respect-
ively [32]. Taking blaCTX-M-9 (AJ416345) as the
basis for comparison, the other blaCTX-M genes
differed by one bp each in the region of the
forward primer (A228G or T216C), and by two
bp each in the region of the reverse primer
(G711A and T705C or T705G). These mismatches
were taken into account in the primer sequences
chosen. In the present validation assay with six
different CTX-M-genes from two phylogenetic
CTX-M-groups, i.e., the CTX-M-1-like and CTX-
M-9-like groups, all genes were detected. Hence,
most of the CTX-M genes should have been
covered with the single PCR used in the present
study.
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The CAZ MICs for isolates EN-293 and EN-331,
producing only CTX-M ESBLs, were comparable
to the MICs reported previously for CTX-M-16
(8 mg ⁄L) and CTX-M-9 (1 mg ⁄L)-producing
strains [33]. In contrast, isolates EN-335 and EN-
337, producing ESBLs of the CTX-M-9-group plus
SHV-12, had CAZ MICs > 256 mg ⁄L. Transfer of
the blaCTX-M genes to Esch. coli (e.g., by conjuga-
tion) would be necessary for more detailed
characterisation.
ESBL genes can be part of plasmids, transpo-
sons or integrons. In a survey of ESBL-producing
Enterobacteriaceae in China, ESBL genes identi-
ﬁed in isolates of the E. cloacae complex included
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blaCTX-M-9, blaCTX-M-14 and blaSHV-12, but no plas-
mid carrying the ESBL genes was identiﬁed [23].
Recently, a new type of chromosomal class 1
integron (In60) carrying blaCTX-M-9 was character-
ised [34]. In a study of the dissemination of CTX-
M-producing Enterobacteriaceae in French hospi-
tals, most blaCTX-M genes were located on class 1
integrons, but one, blaCTX-M-9, was located on In60
[35]. Class 1 integrons carrying ESBL genes are
typically multiresistance integrons harbouring
various aminoglycoside, trimethoprim and SXT
resistance genes [36]. The ESBL isolates in the
present study were all resistant to SXT, GEN and
TOB, suggesting that class 1 integrons are
involved in the dissemination of ESBL genes in
German strains of the E. cloacae complex. In
Germany, resistance rates for members of the E.
cloacae complex to SXT and GEN are c. 7% and
5%, respectively [31], similar to the rate found in
the present study. The strong correlation between
ESBLs and SXT resistance has been observed in
most other studies [13,22,27,37,38], although there
are exceptions [14]. All ESBL-producers in the
present study belonged to a single phylogenetic
cluster (VIII) of the E. cloacae complex, although
this represented only 34% of total isolates. In
contrast, cluster III comprised more isolates, but
did not contain any ESBL-producers. This un-
equal distribution suggests that mobile genetic
elements harbouring ESBL genes might move
more easily within particular genetic clusters of
the E. cloacae complex, but transfer less easily to
other genetic clusters.
Induction and hyper-production of Bush class 1
b-lactamases represent the main mechanisms of
ESC resistance in the E. cloacae complex. The
percentage of isolates resistant to ESCs varies
widely, ranging from 5 to 63% for CTX, from 6 to
59% for CAZ, and from 0.2 to 9% for FEP [1]. The
40% prevalence of ESC-resistant isolates found in
the present study was in agreement with a
previous study in 2001 [31], which reported that
30% of isolates were resistant to CTX, 21% to
CAZ, and 3% to FEP. Detection of ESBLs in a
background of Bush class 1 b-lactamase produc-
tion is difﬁcult [5], but the PM ⁄PML Etests used
in the present study detected four of ﬁve ESBL-
producing isolates of the E. cloacae complex with
good speciﬁcity. Nevertheless, a combination of
molecular and phenotypic tests seems to be the
most accurate approach for detecting ESBL genes
in bacteria producing Bush class 1 b-lactamases.
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